Warning: file_get_contents(https://multipass.sense-studios.com/check_token/-1?url=%2Fspecialisation%2Foncology%2Fasco-gu-2022%2Ffavourable-pathologic-response-rate-with-neoadjuvant-chemotherapy-in-high-risk-upper-tract-urothelial-carcinoma%2F&agent=CCBot%2F2.0+%28https%3A%2F%2Fcommoncrawl.org%2Ffaq%2F%29&name=dev.mc.sense-studios.com&ip=3.93.74.25&categories=Conference+Report+Article%7CUrothelial+Carcinoma%7CASCO+GU+2022%7COncology%7CGenitourinary+Cancer%7CUrology&conference=ASCO+GU+2022): failed to open stream: HTTP request failed! HTTP/1.1 500 Internal Server Error in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 114

Notice: Trying to get property 'status' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 117

Notice: Trying to get property 'access_type' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 123
Favourable pathologic response rate with neoadjuvant chemotherapy in high-risk upper tract urothelial carcinoma - Medical Conferences

Home > Oncology > ASCO GU 2022 > Urothelial Carcinoma > Favourable pathologic response rate with neoadjuvant chemotherapy in high-risk upper tract urothelial carcinoma

Favourable pathologic response rate with neoadjuvant chemotherapy in high-risk upper tract urothelial carcinoma

Presented By
Dr Wesley Yip, Memorial Sloan Kettering Cancer Center, NY, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASCO GU 2022
Trial
Phase 2
In a phase 2 trial, neoadjuvant chemotherapy with gemcitabine plus cisplatin had a favourable pathologic response rate in patients with high-risk upper tract urothelial carcinoma.

Upper tract urothelial carcinoma is a rare but deadly disease; 5-year cancer-specific mortality rates for T2–T4 disease ranges from 21% to 59%. Irrespective of stage, patients with high-grade disease have a significantly worse prognosis [1]. Previously, the POUT trial (NCT01993979) demonstrated that adjuvant gemcitabine-platinum chemotherapy improves disease-free survival in patients with advanced upper tract urothelial carcinoma [2]. In addition, neoadjuvant chemotherapy has proven survival benefits for invasive urothelial carcinoma of the bladder, yet its role in upper tract urothelial carcinoma remains undefined.

The current multicentre, prospective, single-arm, phase 2 study (NCT01261728) evaluated neoadjuvant chemotherapy with gemcitabine and cisplatin in patients with high-risk upper tract urothelial carcinoma. A total of 57 patients received up to 4 cycles of gemcitabine/cisplatin prior to surgical resection and lymph node dissection; 40 participants (70%) tolerated all 4 cycles of gemcitabine/cisplatin, and all participants proceeded to surgery. The primary study endpoint was pathologic response rate (defined as <pT2N0). Dr Wesley Yip (Memorial Sloan Kettering Cancer Center, NY, USA) presented the results [3].

Among 57 patients evaluated, 36 (63%) demonstrated pathologic response, meeting the primary endpoint of the study. A complete response was noted in 11 patients (19%), defined as pT0N0. With a median follow-up of 3.1 years among survivors, 2- and 5-year progression-free survival (PFS) was 78% and 65%; 2- and 5-year overall survival (OS) was 93% and 79%. Participants demonstrating pathologic response had improved PFS and OS compared with those who did not (2-year PFS 91% vs 52%, P<0.001; 2-year OS 100% vs 80%, P<0.001). Overall, the chemotherapy was well tolerated.

“The results show a favourable pathologic response rate with neoadjuvant chemotherapy in patients with high-risk upper tract urothelial carcinoma and this might be considered a new standard of care option for these patients,” concluded Dr Yip.

  1. Olgac S, et al. Am J Surg Pathol. 2004;28:1545–1552.

  2. Britle A, et al. Lancet. 2020;395:1268–1277.

  3. Yip W, et al. Final results of a multicenter prospective phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy in patients with high-grade upper tract urothelial carcinoma. Abstract 440, ASCO GU 2022, 17–19 February.

 

Copyright ©2022 Medicom Medical Publishers



Posted on